Skip to content

US · TSHA · BIOTECHNOLOGY

Taysha Gene Therapies, Inc. (TSHA) intrinsic value and stock valuation

$3.72as of 2026-11-21 · Mkt cap 2.1B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Taysha Gene Therapies, Inc. DCF and intrinsic value

InvestorsCraft values TSHA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from TSHA’s statements →

Taysha Gene Therapies, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Dallas, TX 75247 tayshagtx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$9.77M
20192025
Net income
-$-109M
20192025
Free cash flow
-$-93.83M
20192025
Total equity
$246.9M-0.3% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$9.77M$8.33M$15.5M$2.5M$0.00
Operating income-$-110.5M-$-91.46M-$-72.44M-$-126.03M-$-173.27M
Net income-$-109M-$-89.3M-$-111.57M-$-166.01M-$-174.52M
EPSd-$-340.93K-$-357.01K-$-960.82K-$-3.78M-$-4.64M
Operating cash flow-$-93.09M-$-81.22M-$-73.02M-$-88.39M-$-117.04M
Capital expenditure-$-740K-$-370K-$-7.37M-$-24.87M-$-21.55M
Free cash flow-$-93.83M-$-81.6M-$-80.39M-$-113.26M-$-138.6M
Total assets$343.3M$160.4M$172.7M$126.3M$214M
Total debt$18.2M$63.2M$61.1M$59.9M$63.1M
Net debt-$-301.6M-$-75.86M-$-82.83M-$-27.95M-$-86.01M
Total equity$246.9M$71.5M$74.9M$950K$95.4M
Cash and short-term investments$319.8M$139M$143.9M$87.9M$149.1M
Income statement
20252024202320222021
Revenue$9.77M$8.33M$15.5M$2.5M$0.00
Cost of revenue$0.00$0.00$0.00$2.49M$0.00
Gross profit$9.77M$8.33M$15.5M$10K$0.00
Research and development expenses$86.4M$66M$56.8M$91.2M$131.9M
Selling, general and administrative expenses$33.9M$29M$30.1M$34.9M$41.3M
Other expenses$0.00$4.84M$1.06M$0.00$0.00
Operating expenses$120.3M$99.8M$87.9M$126M$173.3M
Cost and expenses$120.3M$99.8M$87.9M$128.5M$173.3M
Interest income$9.22M$6.94M$3.57M$250K$170K
Interest expense$60K$100K$5M$3.8M$1.43M
Depreciation and amortization$1.15M$1.25M$1.37M$2.49M$490K
Ebitda-$-107.79M-$-87.95M-$-105.2M-$-159.73M-$-172.6M
Operating income-$-110.5M-$-91.46M-$-72.44M-$-126.03M-$-173.27M
Total other income/expenses, net$1.5M$2.16M-$-39.13M-$-39.99M-$-1.26M
Income before tax-$-109M-$-89.3M-$-111.57M-$-166.01M-$-174.52M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-109M-$-89.3M-$-111.57M-$-166.01M-$-174.52M
Weighted average shares outstanding$319.7M$250.1M$116.1M$44M$37.7M
Weighted average diluted shares outstanding$319.7M$250.1M$116.1M$44M$37.7M
Balance sheet
20252024202320222021
Cash and short-term investments$319.8M$139M$143.9M$87.9M$149.1M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$324.7M$142.1M$149.9M$96.4M$159.6M
Property, plant and equipment, net$16.2M$15.9M$20.4M$25.9M$50.6M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$2.31M$0.00$0.00$0.00$2.64M
Total non-current assets$18.7M$18.2M$22.9M$29.9M$54.4M
Total assets$343.3M$160.4M$172.7M$126.3M$214M
Accounts payable$6.28M$3.59M$6.37M$11M$21.8M
Short-term debt$0.00$1.88M$1.65M$1.52M$0.00
Deferred revenue$0.00$9.77M$18.1M$33.6M$0.00
Total current liabilities$26.6M$26.2M$36.8M$62.8M$51.8M
Long-term debt$18.2M$61.3M$59.5M$58.4M$63.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$69.8M$62.6M$61M$62.5M$66.8M
Capital lease obligations$0.00$19.2M$20.6M$22M$25.9M
Total liabilities$96.4M$88.8M$97.8M$125.3M$118.6M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-711.3M-$-602.3M-$-513.01M-$-401.44M-$-235.65M
Accumulated other comprehensive income (loss)-$-190K-$-4.03M$0.00$0.00$0.00
Total equity$246.9M$71.5M$74.9M$950K$95.4M
Total investments$2.31M$0.00$0.00$0.00$2.64M
Total debt$18.2M$63.2M$61.1M$59.9M$63.1M
Net debt-$-301.6M-$-75.86M-$-82.83M-$-27.95M-$-86.01M
Cash flow statement
20252024202320222021
Net income-$-109M-$-89.3M-$-111.57M-$-166.01M-$-174.52M
Depreciation and amortization$1.15M$1.25M$1.37M$1.17M$490K
Stock-based compensation$13.3M$13.1M$7.91M$18M$18.2M
Change in working capital-$-5.37M-$-12.47M-$-18.01M$18.5M$28.7M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-150K-$-2.92M-$-2.29M-$-7.8M$14.5M
Net cash provided by operating activities-$-93.09M-$-81.22M-$-73.02M-$-88.39M-$-117.04M
Investments in property, plant and equipment-$-740K-$-370K-$-3.87M-$-24.87M-$-15.3M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-600K-$-360K-$-7.35M-$-24.93M-$-21.55M
Common stock issued$265.7M$76.8M$140.8M$53.2M-$-360K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$274.6M$76.7M$136.4M$52.1M$39.1M
Net change in cash$180.9M-$-4.9M$56M-$-61.22M-$-99.51M
Cash at end of period$322.5M$141.6M$146.5M$90.5M$151.7M
Operating cash flow-$-93.09M-$-81.22M-$-73.02M-$-88.39M-$-117.04M
Capital expenditure-$-740K-$-370K-$-7.37M-$-24.87M-$-21.55M
Free cash flow-$-93.83M-$-81.6M-$-80.39M-$-113.26M-$-138.6M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Taysha Gene Therapies, Inc.

        Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.

        CEO
        Sean Nolan
        Employees
        99
        Beta
        1.16

        Explore

        Frequently asked questions

        What is the intrinsic value of Taysha Gene Therapies, Inc. (TSHA)?

        Taysha Gene Therapies, Inc. (TSHA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TSHA undervalued?

        TSHA trades at a price of $3.72 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.